JAGX Jaguar Health, Inc.
Company Updates ·
A proxy supplement filed after a stock dividend explains a six-fold increase in shares available under the 2014 Stock Incentive Plan, which stockholders vote on November 6, 2026.
Jaguar issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 cut to a note first sold in 2021. The company reported about 1,945,542 shares outstanding as of September 25, 2026.
The company effected the reverse split on September 17, 2026, and filed a certificate removing the terms of fourteen older preferred stock series from its charter, leaving about 520,088 common shares outstanding.
Jaguar Health exchanged a convertible note and Series Q preferred shares for common stock in September 2026, and issued 535,000 common shares plus a pre-funded warrant to acquire the Napo Therapeutics shares of a minority holder.
Net loss attributable to common stockholders was $12.7 million for the quarter ended June 30, 2026, as U.S. revenue from its two main prescription products now flows to licensee Future Pak under a January 2026 agreement.
Jaguar Health's monthly royalty minimums of $750,000.00 now start October 1, 2026 under both royalty interests, and a Streeterville note matures October 1, 2026 instead of July 1. Streeterville also received common stock for Series Q preferred shares.
Jaguar agreed to sell 161,583 shares and 479,442 pre-funded warrants at $1.56 to Brown Stone Capital Limited. Two days later it issued 286,532 shares to cut a royalty balance by $600,000.
Jaguar Health, Inc., together with its family company Napo Pharmaceuticals, Inc., develops novel prescription drugs derived sustainably from plants for people with complicated gastrointestinal disease states. Napo's crofelemer 125 mg delayed-release tablet, Mytesi, is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In January 2026, Napo entered a United States licensing agreement with an affiliate of privately held Future Pak, LLC, which became the exclusive marketer for Mytesi and for Canalevia-CA1, a crofelemer prescription drug for chemotherapy-induced diarrhea in dogs. Jaguar received $16 million of non-dilutive capital at closing, with an additional $2 million due after post-closing conditions, and may receive up to $20 million in milestone payments. Jaguar will continue to manufacture crofelemer for both products. Napo Therapeutics, S.p.A. is developing new therapies for orphan and rare GI conditions. Magdalena Biosciences, a joint venture with Filament Health Corp., is focused on plant-derived medicines for mental health indications. The OnTarget Phase 3 trial of crofelemer did not meet its primary endpoint for the prespecified analysis of all tumor types and all targeted therapies.
| Product or program | What it is | Stage |
|---|---|---|
| Mytesi | Crofelemer delayed-release tablet for noninfectious diarrhea in adults with HIV/AIDS | FDA-approved |
| Canalevia-CA1 | Crofelemer tablet for chemotherapy-induced diarrhea in dogs | |
| Crofelemer (OnTarget study) | Diarrhea prophylaxis in solid tumor patients receiving targeted therapies | Phase 3; did not meet primary endpoint for all tumor types |
| Magdalena Biosciences program | Plant-derived prescription medicines for mental health indications |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $11.5 million | $11.7 million |
| Research and development | $25.0 million | $16.5 million |
| Net income (loss) | -$53.6 million | -$38.5 million |
| Cash from operations | -$23.7 million | -$29.4 million |
| Cash and equivalents | $968,000 | $8.0 million |
Our latest story on this, dated Sep 21, 2026: "Jaguar Health completes 1-for-15 reverse split and removes old preferred series". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 15, 2026: "Jaguar Health swaps note and preferred shares for common stock". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 15, 2026: "Jaguar Health swaps note and preferred shares for common stock". The story links the filing or release it is based on. Read the story.
Jaguar Health, Inc. trades under the ticker JAGX on NASDAQ.
Jaguar Health, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Jaguar Health, Inc. is 1585608. Its filings are on SEC EDGAR.
171,350,166 shares as of 2018-05-15, per the cover page of its 10-Q filed 2018-05-15.
Our directory records Jaguar Health, Inc. under United States.
Our directory classifies Jaguar Health, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Jaguar Health, Inc. is US47010C8543.
aibio.space lists Jaguar Health, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Jaguar Health, Inc., together with its family company Napo Pharmaceuticals, Inc., develops novel prescription drugs derived sustainably from plants for people with complicated gastrointestinal disease states. Napo's crofelemer 125 mg delayed-release tablet, Mytesi, is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Mytesi: Crofelemer delayed-release tablet for noninfectious diarrhea in adults with HIV/AIDS Stage: FDA-approved.
Canalevia-CA1: Crofelemer tablet for chemotherapy-induced diarrhea in dogs Stage: Not stated.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,5.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a bankruptcy filing. SEC Form 8-K (Items 3.03,7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio